Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review

期刊论文
出版模式：

开放获取
发表日期：

2024年11月27日

查看全文

Simran Kalsi,
Amanda L. Galenkamp,
Rohit Singh,
Atulya Aman Khosla,
Peter McGranaghan,
Jessica Cintolo-Gonzalez

摘要

Purpose of review

As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.

Recent findings

While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms.

Summary

In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.